These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 20100793)

  • 21. The cost-effectiveness of TNF-inhibitors for the treatment of rheumatoid arthritis in Swedish clinical practice.
    Lekander I; Borgström F; Lysholm J; van Vollenhoven RF; Lindblad S; Geborek P; Kobelt G
    Eur J Health Econ; 2013 Dec; 14(6):863-73. PubMed ID: 22990378
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The economic burden of biological therapy in rheumatoid arthritis in clinical practice: cost-effectiveness analysis of sub-cutaneous anti-TNFalpha treatment in Italian patients.
    Benucci M; Li Gobbi F; Sabadini L; Saviola G; Baiardi P; Manfredi M
    Int J Immunopathol Pharmacol; 2009; 22(4):1147-52. PubMed ID: 20074482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Indirect cost-effectiveness analyses of abatacept and rituximab in patients with moderate-to-severe rheumatoid arthritis in the United States.
    Yuan Y; Trivedi D; Maclean R; Rosenblatt L
    J Med Econ; 2010 Mar; 13(1):33-41. PubMed ID: 20001596
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-Effectiveness of Sarilumab Added to Methotrexate in the Treatment of Adult Patients with Moderately to Severely Active Rheumatoid Arthritis Who Have Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    J Manag Care Spec Pharm; 2019 Nov; 25(11):1268-1280. PubMed ID: 31663465
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of sequential therapy with tumor necrosis factor antagonists in early rheumatoid arthritis.
    Davies A; Cifaldi MA; Segurado OG; Weisman MH
    J Rheumatol; 2009 Jan; 36(1):16-26. PubMed ID: 19012363
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting.
    Iannazzo S; Benucci M; Favalli EG
    Clin Exp Rheumatol; 2018; 36(3):479-485. PubMed ID: 29352843
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The cost-effectiveness of etanercept and infliximab for the treatment of patients with psoriatic arthritis.
    Bravo Vergel Y; Hawkins NS; Claxton K; Asseburg C; Palmer S; Woolacott N; Bruce IN; Sculpher MJ
    Rheumatology (Oxford); 2007 Nov; 46(11):1729-35. PubMed ID: 17956918
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The cost-effectiveness of infliximab (Remicade) in the treatment of rheumatoid arthritis in Sweden and the United Kingdom based on the ATTRACT study.
    Kobelt G; Jönsson L; Young A; Eberhardt K
    Rheumatology (Oxford); 2003 Feb; 42(2):326-35. PubMed ID: 12595631
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost utility of tumour necrosis factor-α inhibitors for rheumatoid arthritis: an application of Bayesian methods for evidence synthesis in a Markov model.
    Nguyen CM; Bounthavong M; Mendes MA; Christopher ML; Tran JN; Kazerooni R; Morreale AP
    Pharmacoeconomics; 2012 Jul; 30(7):575-93. PubMed ID: 22640174
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-utility analysis of treatment options after initial tumor necrosis factor inhibitor therapy discontinuation in patients with rheumatoid arthritis.
    Karpes Matusevich AR; Lai LS; Chan W; Swint JM; Cantor SB; Suarez-Almazor ME; Lopez-Olivo MA
    J Manag Care Spec Pharm; 2021 Jan; 27(1):73-83. PubMed ID: 33377443
    [No Abstract]   [Full Text] [Related]  

  • 31. Baricitinib for Previously Treated Moderate or Severe Rheumatoid Arthritis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
    Ren S; Bermejo I; Simpson E; Wong R; Scott DL; Young A; Stevenson M
    Pharmacoeconomics; 2018 Jul; 36(7):769-778. PubMed ID: 29502174
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-Effectiveness Analysis of Biopharmaceuticals for Treating Rheumatoid Arthritis: Infliximab, Adalimumab, and Etanercept.
    Gholami A; Azizpoor J; Aflaki E; Rezaee M; Keshavarz K
    Biomed Res Int; 2021; 2021():4450162. PubMed ID: 34877355
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Economic impact of rheumatoid arthritis (RA) biotherapies in France.
    Maravic M
    Joint Bone Spine; 2010 Jul; 77(4):319-24. PubMed ID: 20493751
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab for the treatment of rheumatoid arthritis.
    Bagust A; Boland A; Hockenhull J; Fleeman N; Greenhalgh J; Dundar Y; Proudlove C; Kennedy T; Moots R; Williamson P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():23-9. PubMed ID: 19804686
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling the cost-effectiveness of treatment of rheumatoid arthritis with rituximab using registry data from Southern Sweden.
    Lindgren P; Geborek P; Kobelt G
    Int J Technol Assess Health Care; 2009 Apr; 25(2):181-9. PubMed ID: 19331709
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment persistence with adalimumab, etanercept, or infliximab in combination with methotrexate and the effects on health care costs in patients with rheumatoid arthritis.
    Tang B; Rahman M; Waters HC; Callegari P
    Clin Ther; 2008 Jul; 30(7):1375-84. PubMed ID: 18691998
    [TBL] [Abstract][Full Text] [Related]  

  • 37. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug.
    Kielhorn A; Porter D; Diamantopoulos A; Lewis G
    Curr Med Res Opin; 2008 Sep; 24(9):2639-50. PubMed ID: 18687164
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of real-world infliximab use in patients with rheumatoid arthritis in Sweden.
    Lekander I; Borgström F; Svarvar P; Ljung T; Carli C; van Vollenhoven RF
    Int J Technol Assess Health Care; 2010 Jan; 26(1):54-61. PubMed ID: 20059781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Effect of Dose Escalation on the Cost-Effectiveness of Etanercept and Adalimumab with Methotrexate Among Patients with Moderate to Severe Rheumatoid Arthritis.
    Incerti D; Hernandez EJM; Tkacz J; Jansen JP; Collier D; Gharaibeh M; Moore-Schiltz L; Stolshek BS
    J Manag Care Spec Pharm; 2020 Oct; 26(10):1236-1242. PubMed ID: 32996384
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of two rituximab retreatment regimens for longstanding rheumatoid arthritis.
    Quartuccio L; di Bidino R; Ruggeri M; Schiavon F; Biasi D; Adami S; Punzi L; Cicchetti A; de Vita S
    Arthritis Care Res (Hoboken); 2015 Jul; 67(7):947-55. PubMed ID: 25581074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.